Faruqi & Faruqi, LLP Launches An Investigation Against Imprimis Pharmaceuticals, Inc. (IMMY) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Imprimis Pharmaceuticals, Inc. (“Imprimis Pharmaceuticals” or the “Company”) (NasdaqCM: IMMY) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for an amendment to the Company’s 2007 Incentive Stock and Awards Plan.
Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on July 5, 2013, the Board of Directors recommends that Imprimis Pharmaceuticals’ shareholders vote to approve an amendment to the Company’s 2007 Incentive Stock and Awards Plan to increase the number of shares available for issuance from 2,400,000 to 5,000,000. The issuance of the additional shares could have a substantial dilutive effect on the shares of Imprimis Pharmaceuticals common stock.
If you own common stock in Imprimis Pharmaceuticals and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.